This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

Abstract: Mobile Edge Computing (MEC) is an emerging network architecture designed to enhance Quality of Service (QoS) by bringing computational resources and storage closer to end users. In MEC ...

In case you had any doubt, Elon Musk’s X has an algorithm that favors conservative content posted by political activists over liberal content or posts by traditional news media accounts, according to ...

X is revamping the algorithm that ranks posts in the "For You" feed. The engineering team said it will post changes to the algorithm on GitHub every four weeks, including explainers on changes. The ...

Instagram is back with a new feature that will allow users to "tune" their algorithm to only display the content they prefer to see, which will be first made available to Reels. The feature is still ...

LinkedIn support accidentally revealed its algorithm: it tracks "viewer tolerance," reducing visibility for authors whose posts are consistently ignored. To succeed, diversify content types weekly, ...

Shares in Belgium’s UCB SA soared to a record, while rival MoonLake Immunotherapeutics lost most of its value, after the latter announced late-stage trial data for an experimental skin disease drug ...

The next leg of a huge share-price rally for Belgium’s UCB SA — driven by the success of its Bimzelx skin disease medicine — hinges on key results for a rival drug. The Belgian biotech’s stock could ...

Niels here from the open-source team at Hugging Face. I discovered your work on Arxiv and was wondering whether you would like to submit it to hf.co/papers to improve its discoverability.If you are ...

Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S. spending pledges from some of the world's largest pharmaceutical companies. Now, ...

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...